Overview

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
0
Participant gender:
All
Summary
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Criteria
Inclusion Criteria:

- Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin
infusion with/without sequential tablet treatment can be included into the study. The
local Moxifloxacin product information must be considered.

Exclusion Criteria:

- Contraindications stated in the local Moxifloxacin product information. Warnings and
precautions, stated in the local Moxifloxacin product information must be considered
as potential exclusion criteria.